Filgrastim is a medicine that helps your body make more white blood cells, especially neutrophils. These cells are important for fighting infections. It's often used to treat low white blood cell counts (neutropenia) or to help prepare for certain types of cancer treatments.
Every report comes from a Lived member, sent anonymously.
Have you tried Neupogen (Filgrastim) for Chemotherapy-Induced Febrile Neutropenia?
Filgrastim, sold as Neupogen and as biosimilar versions such as Zarxio and Nivestym, is a prescription injection that raises the number of neutrophils, the white blood cells that form the body's first line of defense against bacterial infection. A low neutrophil count is called neutropenia. Its main danger is that an ordinary infection can become serious quickly, because the body has too few cells to contain it. A biosimilar is a highly similar version of a biologic medicine, with no meaningful difference in safety or effect. Granix (tbo-filgrastim) is a closely related product approved only for shortening severe neutropenia during chemotherapy, in adults and children 1 month and older. The most common use is during cancer chemotherapy. Many chemotherapy drugs temporarily suppress the bone marrow, and filgrastim lowers the chance of febrile neutropenia (fever while the neutrophil count is very low), a complication that often leads to hospital care. It is also used to speed neutrophil recovery after chemotherapy for acute myeloid leukemia (AML) and after a bone marrow transplant, and to move blood-forming stem cells out of the marrow and into the bloodstream so they can be collected for a person's own later transplant. Outside cancer care, filgrastim is a long-term treatment for people with symptomatic severe chronic neutropenia, whether inherited (congenital), cyclic or of unknown cause (idiopathic), where it reduces fevers, infections and mouth sores. It is also approved to improve survival after exposure to radiation doses high enough to damage the bone marrow. Not everyone on chemotherapy needs it. Cancer specialists generally recommend preventive use when a chemotherapy regimen carries roughly a 20% or higher chance of febrile neutropenia, or at lower risk when a person's age, medical history or disease makes infection more likely.
The body makes its own version of filgrastim's active protein, called granulocyte colony-stimulating factor (G-CSF). G-CSF is a signal that tells the bone marrow to produce more neutrophils and help them mature, and it also makes those neutrophils better at attacking bacteria. Filgrastim is a manufactured copy of G-CSF, so an injection strengthens that signal at a time when the marrow is struggling to keep up. Its effect is largely limited to neutrophils: it does not raise red blood cells or platelets, and it does not treat cancer or an infection directly. Its job is to shorten the stretch of time when the neutrophil count is dangerously low. At higher doses it also drives stem cells out of the marrow into the blood, which is why it is used before stem cell collection.
Filgrastim is given as an injection under the skin, usually once a day, or in the hospital through a vein. The dose is based on body weight and the reason for treatment. Many people, or a caregiver, give the injections at home using a prefilled syringe or a vial, after the care team has shown them how to measure the dose and inject. Common sites are the outer upper arm, abdomen, thigh or upper outer buttock. With chemotherapy, filgrastim is started at least 24 hours after the chemotherapy dose and is not given in the 24 hours before the next one, because rapidly dividing marrow cells may be more vulnerable to chemotherapy. Daily injections typically continue for up to about two weeks, until blood tests show the neutrophil count has passed its lowest point and recovered. For stem cell collection, injections start at least four days before the first collection and continue until the last. People with severe chronic neutropenia usually inject every day, or twice a day for some congenital forms, for the long term. This daily schedule is what sets filgrastim apart from pegfilgrastim (Neulasta), a long-acting relative given once per chemotherapy cycle. If a dose is missed, contact the care team for instructions. Keep syringes and vials in the refrigerator in their carton, out of direct sunlight, and do not freeze or shake them. The needle cap on the Neupogen prefilled syringe contains natural rubber, a latex derivative, which matters for anyone with a latex allergy.
Bone pain is the side effect people most often notice, along with back, joint or limb aches, and it is especially common, along with headache, at the higher doses used for stem cell collection. Fever, rash, nausea, tiredness, dizziness and cough were also more frequent with filgrastim than with placebo in chemotherapy studies, although some of these overlap with chemotherapy's own effects. Mention pain that is hard to manage to the care team. A few rare reactions need quick action. Pain in the upper left side of the abdomen or at the tip of the left shoulder can signal an enlarged or ruptured spleen, which has occasionally been fatal; call the care team right away. New shortness of breath, with or without fever, should also be reported right away, because it can be the start of acute respiratory distress syndrome (ARDS), a serious lung injury. Rarer inflammatory reactions can affect the kidneys, the small blood vessels of the skin or large blood vessels such as the aorta. Report these to the care team promptly: swollen ankles, dark or bloody urine or passing much less urine; a purple or red spotty rash; or fever with pain in the belly, back or neck that has no other explanation. Signs of a serious allergic reaction, such as swelling of the face, wheezing, trouble breathing, a racing heart or feeling faint, need emergency medical care. Most such reactions occur with the first doses, and symptoms can come back within days after treatment for the reaction has stopped.
Filgrastim should not be used by anyone who has had a serious allergic reaction to filgrastim or to pegfilgrastim, and it is stopped permanently if one occurs. People with sickle cell disease face a specific danger: filgrastim products can trigger severe, sometimes fatal sickle cell crises. Anyone with a sickle cell disorder should discuss this risk with the prescriber before treatment. Myelodysplastic syndrome (MDS, a bone marrow disorder that can progress to leukemia) and AML have been reported in people with congenital neutropenia treated with filgrastim, and in people with breast or lung cancer who received it along with chemotherapy or radiation. In congenital neutropenia these conditions also occur without treatment, and the added risk from filgrastim is not fully defined. Ongoing tiredness, fever and easy bruising or bleeding are worth reporting, and blood counts are monitored during long-term use. Using it at the same time as both chemotherapy and radiation is avoided. Because it makes the marrow more active, it can temporarily change the appearance of bone scans, so mention it before nuclear imaging. Studies, mainly in women with severe chronic neutropenia, have not linked use during pregnancy to birth defects or miscarriage, but the data are limited; discuss pregnancy or plans for pregnancy with the prescriber.
Neutrophil counts typically rise within a day or two of starting, but that early rise does not mean the job is done. With chemotherapy, injections usually continue daily until the count has passed through its lowest point and recovered. A complete blood count, which includes the neutrophil and platelet counts, is usually checked about twice a week, and filgrastim is stopped once the neutrophil count is high enough, because pushing it higher adds no benefit. After stopping, the count usually falls by about half within one to two days and returns to its earlier level within about a week. Filgrastim lowers the chance of a serious infection during chemotherapy but does not remove it, so the cancer team's instructions about reporting fever still apply. For severe chronic neutropenia, treatment is long term because the benefit lasts only while injections continue. Before starting, the diagnosis is confirmed with repeated blood counts and a bone marrow test, since starting filgrastim too early can hide another cause of low neutrophils. Blood counts are checked often in the first month and after any dose change, then monthly through the first year, and less often once things are stable. For stem cell collection, the course is short: several days of injections, with collection by leukapheresis (a procedure that filters stem cells from the blood) commonly on the fifth to seventh day.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Neupogen (Filgrastim), what you've noticed, or ask the community a question.